Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Acquire Norwegian Magnetic Bead Maker Dynal Biotech for $380M

NEW YORK, Feb. 8 (GenomeWeb News) - Invitrogen plans to purchase Norwegian magnetic bead maker Dynal Biotech from its majority owner, Nordic Capital, and a co-investor for 2.5 billion Norwegian kroner ($380 million), the company said today.

 

Dynal Biotech, based in Oslo, provides magnetic bead-based separation technologies that are used in cell separation and purification, cell stimulation, protein research, nucleic acid research, and microbiology.

 

Invitrogen plans to integrate the company's Dynabead technology to enhance its own products for assay development, RNA interference, DNA cloning, proteomic analysis, and screening applications. It also plans to couple Dynabeads with targeted antibodies from Zymed Laboratories, another company Invitrogen is currently acquiring.

 

The acquisition is scheduled to close by the end of March. Invitrogen expects Dynal, which has more than 400 employees in Norway, the US, the UK, and China, to create $74 million in revenues from April until the end of the year.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.